Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Similar local control between phenol- and ethanol-treated giant cell tumors of bone.

Lin WH, Lan TY, Chen CY, Wu K, Yang RS.

Clin Orthop Relat Res. 2011 Nov;469(11):3200-8. doi: 10.1007/s11999-011-1962-3. Epub 2011 Jul 6.

2.

Phenol as an adjuvant for local control in the treatment of giant cell tumour of the bone.

Dürr HR, Maier M, Jansson V, Baur A, Refior HJ.

Eur J Surg Oncol. 1999 Dec;25(6):610-8.

PMID:
10556009
3.

Soft tissue extension increases the risk of local recurrence after curettage with adjuvants for giant-cell tumor of the long bones.

van der Heijden L, van de Sande MA, Dijkstra PD.

Acta Orthop. 2012 Aug;83(4):401-5. doi: 10.3109/17453674.2012.711193. Epub 2012 Aug 10.

4.

Treatment of benign giant cell tumours of bone in Singapore.

Lim YW, Tan MH.

Ann Acad Med Singapore. 2005 Apr;34(3):235-7.

5.

Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy.

Arbeitsgemeinschaft Knochentumoren., Becker WT, Dohle J, Bernd L, Braun A, Cserhati M, Enderle A, Hovy L, Matejovsky Z, Szendroi M, Trieb K, Tunn PU.

J Bone Joint Surg Am. 2008 May;90(5):1060-7. doi: 10.2106/JBJS.D.02771.

PMID:
18451399
6.

Giant cell tumor of bone: risk factors for recurrence.

Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH.

Clin Orthop Relat Res. 2011 Feb;469(2):591-9. doi: 10.1007/s11999-010-1501-7. Epub 2010 Aug 13.

7.

Giant cell tumor with pathologic fracture: should we curette or resect?

van der Heijden L, Dijkstra PD, Campanacci DA, Gibbons CL, van de Sande MA.

Clin Orthop Relat Res. 2013 Mar;471(3):820-9. doi: 10.1007/s11999-012-2546-6. Erratum in: Clin Orthop Relat Res. 2012 Dec;470(12):3626.

8.

Liquid nitrogen or phenolization for giant cell tumor of bone?: a comparative cohort study of various standard treatments at two tertiary referral centers.

van der Heijden L, van der Geest IC, Schreuder HW, van de Sande MA, Dijkstra PD.

J Bone Joint Surg Am. 2014 Mar 5;96(5):e35. doi: 10.2106/JBJS.M.00516.

PMID:
24599207
9.

Recurrent giant cell tumor of long bones: analysis of surgical management.

Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH.

Clin Orthop Relat Res. 2011 Apr;469(4):1181-7. doi: 10.1007/s11999-010-1560-9. Epub 2010 Sep 16.

10.

Recurrence of curetted and bone-grafted giant-cell tumours with and without adjuvant phenol therapy.

Trieb K, Bitzan P, Lang S, Dominkus M, Kotz R.

Eur J Surg Oncol. 2001 Mar;27(2):200-2.

PMID:
11289759
11.

Ethanol as a local adjuvant for giant cell tumor of bone.

Jones KB, DeYoung BR, Morcuende JA, Buckwalter JA.

Iowa Orthop J. 2006;26:69-76.

12.

Giant cell tumors of the sacrum--a nationwide study on midterm results in 26 patients after intralesional excision.

van der Heijden L, van de Sande MA, van der Geest IC, Schreuder HW, van Royen BJ, Jutte PC, Bramer JA, Öner FC, van Noort-Suijdendorp AP, Kroon HM, Dijkstra PD.

Eur Spine J. 2014 Sep;23(9):1949-62. doi: 10.1007/s00586-014-3263-5. Epub 2014 Mar 11.

PMID:
24614982
13.

Low-grade chondrosarcoma of long bones treated with intralesional curettage followed by application of phenol, ethanol, and bone-grafting.

Verdegaal SH, Brouwers HF, van Zwet EW, Hogendoorn PC, Taminiau AH.

J Bone Joint Surg Am. 2012 Jul 3;94(13):1201-7. doi: 10.2106/JBJS.J.01498.

PMID:
22760388
14.

Conservative treatment of Campanacci grade III proximal humerus giant cell tumors.

Lackman RD, Crawford EA, King JJ, Ogilvie CM.

Clin Orthop Relat Res. 2009 May;467(5):1355-9. doi: 10.1007/s11999-008-0583-y. Epub 2008 Nov 6.

15.

Supplemental Bone Grafting in Giant Cell Tumor of the Extremity Reduces Nononcologic Complications.

Benevenia J, Rivero SM, Moore J, Ippolito JA, Siegerman DA, Beebe KS, Patterson FR.

Clin Orthop Relat Res. 2017 Mar;475(3):776-783. doi: 10.1007/s11999-016-4755-x.

PMID:
26932739
16.

Alternative surgical treatment for giant-cell reparative granuloma in the metacarpal, using phenol and ethanol adjuvant therapy.

Yoshida T, Sakamoto A, Tanaka K, Matsuda S, Oda Y, Iwamoto Y.

J Hand Surg Am. 2007 Jul-Aug;32(6):887-92.

PMID:
17606072
17.

Recurrence after and complications associated with adjuvant treatments for sacral giant cell tumor.

Ruggieri P, Mavrogenis AF, Ussia G, Angelini A, Papagelopoulos PJ, Mercuri M.

Clin Orthop Relat Res. 2010 Nov;468(11):2954-61. doi: 10.1007/s11999-010-1448-8.

18.

Joint preservation after extensive curettage of knee giant cell tumors.

Ayerza MA, Aponte-Tinao LA, Farfalli GL, Restrepo CA, Muscolo DL.

Clin Orthop Relat Res. 2009 Nov;467(11):2845-51. doi: 10.1007/s11999-009-0913-8. Epub 2009 Jun 10.

19.

Local Treatment with Adjuvant Therapy for Central Atypical Cartilaginous Tumors in the Long Bones: Analysis of Outcome and Complications in One Hundred and Eight Patients with a Minimum Follow-up of Two Years.

Dierselhuis EF, Gerbers JG, Ploegmakers JJ, Stevens M, Suurmeijer AJ, Jutte PC.

J Bone Joint Surg Am. 2016 Feb 17;98(4):303-13. doi: 10.2106/JBJS.O.00472.

PMID:
26888678
20.

Local recurrence after curettage treatment of giant cell tumors in peripheral bones: retrospective study by the GSF-GETO (French Sarcoma and Bone Tumor Study Groups).

Gouin F, Dumaine V; French Sarcoma and Bone Tumor Study Groups GSF-GETO..

Orthop Traumatol Surg Res. 2013 Oct;99(6 Suppl):S313-8. doi: 10.1016/j.otsr.2013.07.006. Epub 2013 Aug 23.

Supplemental Content

Support Center